On these bases, small molecule inhibitors of nicotinamide phosphoribosyl-transferase (NAMPT) essential for the NAD+ requiring glycolytic GAPDH step have been employed both in vitro and in vivo as a proof-of-concept for Myc-driven glycolytic targeting in GBM. The gene discussed is MYC; the disease is glioblastoma.